Ropes & Gray represented Apollo Therapeutics in the transaction. Apollo Therapeutics Group Limited (“Apollo”) and Sunshine Lake Pharma Co., Ltd. have entered into an exclusive license...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Ionis Pharmaceuticals in the deal. Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka)...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Fulcrum Therapeutics on the transaction. Fulcrum Therapeutics, Inc. (Fulcrum) (Nasdaq: FULC) announced it has entered into a collaboration and license agreement with...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Ovid Therapeutics on the deal. Ovid Therapeutics announced a collaboration with Graviton Bioscience Corporation under which Ovid obtained exclusive rights to develop...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Pfizer in the deal. Pfizer announced its collaboration arrangement with Biohaven Pharmaceutical Company to commercialize rimegepant, a therapy approved in the U.S. as...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Sunovion Pharmaceuticals on the deal while Cooley represented Otsuka Pharmaceutical. Sunovion Pharmaceuticals Inc., a subsidiary of Japan’s Sumitomo Dainippon Pharma, signed a...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised iTeos Therapeutics in the deal. iTeos Therapeutics closed a collaboration with global healthcare leader GSK to co-develop and co-commercialize an anti-TIGIT monoclonal...
You must be a Standard 1 Year member to access this content.
